You searched for "intravitreal"

466 results found

Avastin vs. Volon A for diabetic macular oedema

This prospective randomised interventional clinical trial compared 30 diabetic patients with macular oedema treated with either intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A). One group initially received three injections of 2.5 mg Avastin in monthly intervals whilst the...

Evaluation of fluocinolone acetonide in the management of BRC

This is a single-centre, retrospective, intervention study of 15 eyes of birdshot retinochoroiditis (BRC) patients who received Iluvein, with a mean follow-up period of 31 months. Five eyes had previously received dexamethasone intravitreal implant 0.7mg (Ozurdex). Fluorescein angiography (FA) showed...

Practice patterns in managing exogenous endophthalmitis

The authors of this study conducted a global survey of medical institutions regarding management of exogenous endophthalmitis to assess current practice patterns for this sight-threatening emergency. Thirty-six (of 42 institutions) responded and were included in the analysis. Results were as...

ROP ocular outcomes after Bevacizumab treatment

The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...

Type 3 CNV and anti-VEGF

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Does Ozurdex affect perfusion status in vein occlusion?

Ozurdex (intravitreal dexamethasone implant) has been approved by National Institute of Health & Care Excellence (NICE) for treatment of patients with macular oedema associated with vein occlusion. This study looks at the change in peripheral perfusion status in patients with...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...

Medical Ophthalmological Society Annual Meeting

By Muhammad Adil Seelarbokus, Final Year Medical Student, Newcastle University. With an ever-increasing ageing population with multiple co-morbidities presenting to clinics nowadays, the need for medical ophthalmologists is growing. The Medical Ophthalmological Society’s Annual Meeting seemed to be an excellent...

Ranibizumab safety in pregnancy

Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...